Page 28 - Coronavirus Vaccine

Data story: India records 862 new Covid-19 cases, lowest in 196 days

India has so far administered 2,195,665,598 vaccine doses

Latest news LIVE: Delhi's air quality second best on Diwali in seven years

From Diwali celebrations and Cyclone Sitrang to coronavirus cases and air pollution, catch all the latest developments from across the globe here

LIVE: Rishi Sunak says will run for Britain's PM again

'I want to fix our economy, unite our Party and deliver for our country,' tweets Sunak

Data story: India adds 2,112 new Covid cases; active tally at 24,043

India has added 14,321 cases in the past 7 days

Covid vaccine to cost $110-$130 per dose after US govt stops buying: Pfizer

Pfizer will charge USD 110 to USD 130 for a dose of its COVID-19 vaccine once the U.S. government stops buying the shots, but the drugmaker says it expects many people will continue receiving it for free. Pfizer executives said the commercial pricing for adult doses could start early next year, depending on when the government phases out its program of buying and distributing the shots. The drugmaker said it expects that people with private health insurance or coverage through public programs like Medicare or Medicaid will pay nothing. The Affordable Care Act requires insurers to cover many recommended vaccines without charging any out-of-pocket expenses. A spokesman said the company also has an income-based assistance program that helps eligible U.S. residents with no insurance get the shots. The price would make the two-dose vaccine more expensive for cash-paying customers than annual flu shots. Those can range in price from around $50 to $95, depending on the type, according to

Pfizer's Covid vaccine price hike seen giving revenue boost for yrs: Report

Outside the United States, Pfizer said it already has contracts with governments in many developed markets that extend through 2023 with prices that have already been set

Latest LIVE: Modi blames previous govts for 'neglecting' religious places

From PM Modi's Kedarnath, Badrinath visit to coronavirus cases, catch all the latest developments from across the globe here

Covishield production stopped in Dec 2021, says Serum Institute's CEO

CEO Adar Poonawalla said Serum Institute of India stopped producing Covishield vaccine from December 2021 and of the total stock available at that time, about 100 million doses had already expired

HPV vaccine prodn delayed due to Covid, to start supply in early 2023: SII

Serum Institute of India (SII) had to defer HPV vaccine production by two years due to the focus on COVID, and will start supplying small quantities of the dose to the Indian government in early 2023, a top official has said. Exports will have to wait till 2024, its chief executive Adar Poonawalla told reporters here on Thursday evening, adding that the company has to build a scale of manufacturing to over 150 million for that. HPV vaccines prevent certain kinds of cervical cancer. SII is the world's largest vaccine manufacturer which rushed with the production of multiple COVID vaccines at its facilities located here once the shot was approved for use. "The HPV facility was used by the COVID vaccines during the pandemic. That's why we had to delay the larger launch to next year," Poonawalla said, speaking on the sidelines of an event. "We will be making a very small quantity and launching with the Indian government in the first quarter of next year. Followed by a capacity for 70

Data story: India logs 2,119 new Covid cases; death toll at 528,953

India has so far administered 2,195,097,574 vaccine doses

Global rollout of 12 bn vaccine doses largest-ever but access an issue: WHO

World Health Organization (WHO) director-general Dr Tedros Adhanom Ghebreyesus on Thursday said global roll-out of more than 12 billion COVID-19 vaccine doses is the largest and fastest in human history. Addressing the annual general meeting of the Developing Countries Vaccine Manufacturers Network (DCVMN) virtually, he flagged the issue of inequities in access to COVID-19 vaccines. The three-day event is being co-hosted by the Pune-based Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, said a statement. Global roll-out of more than 12 billion COVID-19 vaccine doses is the largest and fastest in history with an estimated 60 per cent doses produced by manufacturers in developing countries. Despite this achievement, stark inequities in access to COVID-19 vaccines remain," he said. "These inequities are due partly to the fact that globally vaccine production is too concentrated. To address this, the WHO and our partners have established the mRNA Tech

Developing nations' vaccine manufacturers bat for pandemic treaty

It's time to focus on routine immunisation: Mandaviya

SII stopped Covishield production in Dec 2021, says CEO Adar Poonawalla

Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Thursday said the vaccine manufacturer stopped the production of Covishield vaccine starting December 2021, and of the total stock available at that time, around 100 million doses had already got expired. Speaking to reporters on the sidelines of the annual general meeting of Developing Countries Vaccine Manufacturers Network (DCVMN), he said booster vaccines have no demand as there is general lethargy among people and also because they are fed up with the pandemic. "Since December 2021, we stopped the production (of Covishield). We had a stock of a few hundred million doses at that time and of that, 100 million doses have already expired," said Poonawalla when asked about the update on the Covishield vaccine. He said the SII's vaccines are allowed to be mixed. "Now, Covovax should be allowed in two weeks. So I think they will and should probably have the policy to mix boosters. If WHO allowed it, then .

Data story: India adds 2,141 new Covid cases; active tally at 25,510

India has added 15,198 cases in the past 7 days

Winter is coming: New Covid-19 variants prompt alert for illness season

Health minister Mansukh Mandaviya holds review meeting as experts call for continued vigil

Omicron sub-variant BF.7 behind China surge sparks concerns in India

Amid rising concerns around Omicron sub-variant that caused surge in China, the network of government scientists and labs responsible for genome-sequencing strains of Covid-19 virus are likely to meet

Data story: India adds 1,542 new Covid cases; death toll at 528,913

India has added 16,036 cases in the past 7 days

India's Covid-19 vaccination not over yet, govt still has 30 mn in stock

With already more than 200 Cr vaccine (first, second and precautionary) doses administered across the country so far

Govt not to procure fresh Covid vaccines; surrenders Rs 4k cr from budget

The government's Covid vaccination programme is in its final leg with the Health Ministry deciding against procuring more vaccines as of now and surrendering Rs 4,237 crore, or nearly 85 per cent of the 2022-23 budget allocation for inoculation purposes, to the Finance Ministry. Official sources told PTI that more than 1.8 crore doses are still available with the governments at the Centre and in states and the stock is sufficient to continue the vaccination drive for around six months, given the low uptake of vaccines among people due to declining Covid case burden. Even if the government's stock gets exhausted, Covid vaccines will be available in the market. "Any decision on whether to procure Covid vaccine doses through the government channel or get (fresh) budget allocations for the purpose after six months will depend on the coronavirus situation prevailing in the country at that time," an official source told PTI. As part of the nationwide vaccination drive which began on Janu

Data story: India adds 2,430 new cases of Covid; active tally at 26,618

India has added 17,110 cases in the past 7 days